Biogen To Submit Spinraza To UK's NICE For SMA, While Australia Wants More Data

 
• By Ian Schofield
  
Price - Value
Spinraza's cost effectiveness is being evaluated in the UK and Australia, among other countries.

More from Market Access

More from Pink Sheet